Eiger Biopharmaceuticals (EIGR) Raised to “Buy” at ValuEngine

Eiger Biopharmaceuticals (NASDAQ:EIGR) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Friday.

EIGR has been the subject of several other research reports. Ladenburg Thalmann initiated coverage on shares of Eiger Biopharmaceuticals in a report on Wednesday, January 3rd. They issued a “buy” rating and a $32.00 price objective for the company. Zacks Investment Research raised shares of Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a report on Tuesday, January 9th. Piper Jaffray reaffirmed an “overweight” rating and issued a $17.00 price objective (down previously from $35.00) on shares of Eiger Biopharmaceuticals in a report on Tuesday, January 16th. Oppenheimer reaffirmed a “buy” rating on shares of Eiger Biopharmaceuticals in a report on Wednesday, March 21st. Finally, Wedbush reduced their price objective on shares of Eiger Biopharmaceuticals from $36.00 to $34.00 and set an “outperform” rating for the company in a report on Thursday, March 22nd. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Eiger Biopharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $27.25.

How to Become a New Pot Stock Millionaire

Shares of EIGR traded up $0.65 during midday trading on Friday, hitting $10.85. 72,088 shares of the stock traded hands, compared to its average volume of 141,110. The company has a market cap of $105.79, a price-to-earnings ratio of -2.23 and a beta of 1.58. Eiger Biopharmaceuticals has a 1-year low of $6.10 and a 1-year high of $16.20. The company has a debt-to-equity ratio of 0.58, a quick ratio of 5.85 and a current ratio of 5.85.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last posted its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.09). analysts predict that Eiger Biopharmaceuticals will post -4.22 EPS for the current year.

In other Eiger Biopharmaceuticals news, insider Joanne Quan sold 4,000 shares of the business’s stock in a transaction dated Monday, April 2nd. The shares were sold at an average price of $10.00, for a total value of $40,000.00. Following the sale, the insider now directly owns 4,000 shares in the company, valued at $40,000. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 28.80% of the company’s stock.

A number of institutional investors have recently modified their holdings of EIGR. Prosight Management LP bought a new stake in Eiger Biopharmaceuticals in the fourth quarter worth about $9,469,000. Jennison Associates LLC bought a new stake in Eiger Biopharmaceuticals in the fourth quarter worth about $8,430,000. Armistice Capital LLC bought a new stake in Eiger Biopharmaceuticals in the fourth quarter worth about $5,357,000. Stonepine Capital Management LLC bought a new stake in Eiger Biopharmaceuticals in the fourth quarter worth about $2,093,000. Finally, Unterberg Capital LLC bought a new stake in Eiger Biopharmaceuticals in the fourth quarter worth about $698,000. Hedge funds and other institutional investors own 68.96% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Eiger Biopharmaceuticals (EIGR) Raised to “Buy” at ValuEngine” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://ledgergazette.com/2018/04/13/eiger-biopharmaceuticals-eigr-raised-to-buy-at-valuengine.html.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. Its product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus (HDV) infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply